Pétur Gunnarsson

Pétur Gunnarsson

Auto-generated profile, based on publicly available information

Pétur Gunnarsson

Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
AWAnita Elaine Weidmann
Anita Elaine Weidmann
GPGuðný Björk Proppé
Guðný Björk Proppé
RMRut Matthíasdóttir
Rut Matthíasdóttir
ITIvana TADIĆ
Ivana TADIĆ
PGPétur Sigurdur Gunnarsson
Pétur Sigurdur Gunnarsson
FJFreyja Jónsdóttir
Freyja Jónsdóttir
Background: While medication is a recognized risk factor of delirium, there is currently a lack of detailed information on managing and preventing medication-induced cases. Aim: This review summarizes the information provided in neurology guidelines on medication-induced delirium in patients with and without dementia to inform guidance on prevention and management strategies. Method: A systematic literature review was conducted across 114 neurological and medical organisations, Guideline Central and PubMed. Guidelines, consensus guidelines, white papers, frameworks, protocols, standard procedures, action plans and strategic documents detailing the prevention and management of medication-induced delirium in adults with or without dementia were included. Title and full-text screening was completed independently by two reviewers using PICOS. AGREE II was used to assess reporting quality. A data extraction tool was designed based on the Cochrane Effective Practice and Organization of Care Review Group (EPOC) checklist and a mixed methods approach to synthesis adopted. The systematic review protocol was registered with International Prospective Register of Systematic Reviews (PROSPERO) [ID: CRD42022366025]. Results: Out of 143 guidelines identified, 30 were included. Information for 140 individual medications was extracted. Medications most frequently cited included sedatives (n = 24/80%), opioids (n = 22/73,3%), psychoactive drugs (n = 21/70%) + anti-convulsants (n = 14/46,7%), anti-cholinergic agents (n = 20/66,7%), antihistamines (n = 18/60%), and steroids (n = 16/53,3%). Despite a consistently high-quality rating (n = 19, 63,3%), the detail provided often lacks specificity about pharmacological mechanisms, individual risk, dosing instructions, associated symptoms, therapeutic alternatives and avoidable drug-drug combinations. In relation to dementia, detailed information on the use of antipsychotics, cholinesterase inhibitors and benzodiazepines was extracted. No papers were excluded based on their quality. Conclusion: No single guideline contains enough information on the risk, prevention, and management of medication-induced delirium to sufficiently support clinical decision making.

4 June 2024 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
OPO Palsson
O Palsson
TLTj Love
Tj Love
JWJk Wallman
Jk Wallman
MKMC Kapetanovic
MC Kapetanovic
PGPs Gunnarsson
Ps Gunnarsson
BGB Gudbjornsson
B Gudbjornsson
To study the impact of tumour necrosis factor-α inhibitor (TNFi) therapy on the use of non-steroidal anti inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) in Iceland. This registry cohort study used data from the nationwide database on biologics in Iceland (ICEBIO) and the Icelandic Prescription Medicines Register on disease activity, and filled prescriptions for NSAIDs, to study the period from 2 years before to 2 years after initiation of a first TNFi. Five randomly selected individuals from the general population matched on age, sex, and calendar time for each patient served as comparators. Data from 940 patients and 4700 comparators were included. Patients with arthritis were prescribed 6.7 times more defined daily doses of NSAIDs than comparators (149 vs 22 per year). After TNFi initiation, NSAID use decreased to a mean of 85 DDD per year, or by 42% in RA, 43% in PsA, and 48% in axSpA. At TNFi initiation, the quintile of axSpA patients who used most NSAIDs reported significantly worse pain (mean ± sd 66 ± 21 vs 60 ± 23 mm), global health (70 ± 20 vs 64 ± 23 mm), and Health Assessment Questionnaire score (1.21 ± 0.66 vs 1.02 ± 0.66) than the other patients, whereas no significant differences were observed in the groups with peripheral arthritis. Patients with inflammatory arthritides requiring TNFi therapy use more NSAIDs than matched comparators, and consumption decreased following TNF initiation. Patient-reported measures are not associated with high NSAID use in patients with peripheral arthritis.

10 June 2021 in Pharmacy Education
Verified
Journal Article
Closed access
PDF file
AWAnita Elaine Weidmann
Anita Elaine Weidmann
UGUnnur Karen Guðbjörnsdóttir
Unnur Karen Guðbjörnsdóttir
AGAnna Ingibjörg Gunnarsdóttir
Anna Ingibjörg Gunnarsdóttir
PGPétur Gunnarsson
Pétur Gunnarsson
FJFreyja Jónsdóttir
Freyja Jónsdóttir
Aim: To explore the expectations of Icelandic community pharmacists and final year pharmacy students on future role extensions and associated education needs. Methods: All community pharmacists across Iceland registered with the Pharmaceutical Society of Iceland (LFI) (n=136) and all fourth- and fifth-year pharmacy students enrolled at the Faculty of Pharmaceutical Sciences at the University of Iceland (n=69). An online cross-sectional questionnaire was designed, validated, piloted and analysed using descriptive statistics, logistic regression and content analysis. Results: The response rate was 27.9% (n=38) for community pharmacists and 33.3% (n=23) for fourth- and fifth-year pharmacy students respectively. Of these, 90.2% (n=55) saw the need for community pharmacists’ role extensions and most (n=60, 98.4%) were willing to accept additional education to make role extensions in Iceland possible. Logistic regression identified that students identified the need for pharmacists to be making prescribing recommendations to medical healthcare professionals (p=0.023); for example “Pharmacists should use their knowledge to give advice and collaborate with physicians and other healthcare professionals about drug therapies”. Conclusion: Both community pharmacists and pharmacy students showed a strong willingness to extend their roles in the future. It will require government support to overcome perceived barriers and to develop further education programmes.